ad

Corona Remedies IPO GMP: Day 3 IPO Live Updates

Wed Dec 10 2025

Corona Remedies IPO GMP: Day 3 IPO Live Updates

The Corona Remedies IPO GMP is ₹265.00 as of 10th December 2025. It is a bookbuilding IPO of ₹655.37 crores. This is an entirely fresh issue of 20.70 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 15th December 2025. The face value of Riddhi Display Equipment’s IPO shares is ₹10 per share, and the IPO price band is ₹1008.00 to ₹1062.00 per share. Retail investors can bid for a minimum of 1 lot of 14 shares worth ₹14,868.

Corona Remedies IPO GMP Grey Market Premium

As mentioned earlier, the Corona Remedies IPO GMP currently stands at ₹265.00 per share. Thus, the estimated listing price would be flat at ₹1,327.00. This indicates that the estimated listing gain in this IPO could be 24.95%. Explore the table for Riddhi Display Equipment IPO GMP updates.

GMP DATEIPO PriceGMP PriceEstimated Listing PriceEstimated Gain
10-12-2025₹1,062.00₹265.00₹1327.0024.95%
9-12-2025₹1,062.00₹270.00₹1332.0025.42%
8-12-2025₹1,062.00₹262.00₹1,324.0024.67%
7-12-2025₹1,062.00₹290.00₹1,352.0027.31%
6-12-2025₹1,062.00₹305.00₹1,367.0028.72%
5-12-2025₹1,062.00₹365.00₹1,427.0034.37%
4-12-2025₹1,062.00₹365.00₹1,427.0034.37%
3-12-2025₹1,062.00₹307.00₹1,369.0028.91%
2-12-2025₹1,062.00₹0.00₹138.000.00%

Note: GMP details are subject to change based on market conditions and fluctuations. Check live Corona Remedies IPO GMP status at Univest

Corona Remedies IPO Details

IPO Allotment Date11th December 2025
IPO Open Date8th December 2025
IPO Close Date10th December 2025
Refund Initiation 12th December 2025
Issue Size61,71,101 shares(aggregating up to ₹655.37 Cr)
Face Value₹10 per share
Lot Size14 Shares
Issue Price ₹1,008 to ₹1,062 per share
Issue TypeBookbuilding IPO
Listing AtBSE NSE
Listing Date15th December 2025

Also Read: Corona Remedies IPO GMP & Review: Apply or Avoid?

Explanation

Corona Remedies IPO: Corona Remedies IPO Limited has declared an issue price band of ₹1,008 to ₹1,062 per share. With this IPO, the company allows retail investors to bid for at least 1 lot of 14 shares, each worth ₹14,868. The face value of Corona Remedies IPO Limited shares is ₹10 per share. The shares of Corona Remedies IPO Limited will be listed on BSE and SME on its tentative listing day, 15th December 2025. Scroll down to check GMP updates and Corona Remedies IPO reviews. 

Corona Remedies IPO Objectives

The primary aim of the Corona Remedies IPO is to raise ₹655.37 crores. On the other hand, Corona Remedies has decided to utilise these funds in different ways.

Corona Remedies IPO Registrar

According to recent updates, Bigshare Services Private Limited is the registrar for the Corona Remedies IPO, awaiting to manage the allotment process and initiate refunds. For any queries regarding the Corona Remedies allotment and refund, you can contact Bigshare Services Private Limited at ipo@bigshareonline.com or +91-22-6263 8200.

Corona Remedies IPO Review

Corona Remedies IPO GMP Review

The Corona Remedies IPO has gained neutral ratings from industry experts, brokers, and institutional investors. Corona Remedies Limited’s revenue soared by 18% from ₹1,020.93 crores in March 2024  to ₹1,202.35 crores in March 2025. Moreover, the company’s PAT increased by 65% from ₹90.50 crores in March 2024 to ₹149.43 crores in March 2025. Most analysts recommend applying for this IPO to diversify your investment portfolio. However, we’re waiting for additional ratings to get a clearer picture and will keep posting them to deliver real-time insights. Until then, you can explore the company’s technical analysis to know whether you should apply for the Corona Remedies IPO or not.

Corona Remedies IPO Technicals

Key IndicatorsValue
PE Ratio (Price-to-Earnings) 43.47
EPS (Earnings Per Share)24.23
RoNW24.65%
ROCE41.32%
ROE27.50%
EBITDA Margin20.55%
Price to Book Value10.71
Market Capitalisation₹6,495.20

The PE ratio of Corona Remedies Limited shares is 43.47, and its Earnings Per Share (EPS) stands at 24.43. Thus, the Corona Remedies IPO can deliver gains on its tentative listing date, 12th December 2025. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Corona Remedies Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

IndicatorsPre-IPOPost-IPO
PE Ratio43.4735.15
EPS 24.4330.21

FAQs on Corona Remedies IPO

What is the Corona Remedies IPO GMP?

Ans. Currently, on 10th December 2025, the Corona Remedies GMP (Grey Market Premium) stands at ₹265. It indicates that the estimated listing price could be ₹1,327.00 per share. It is a bookbuilding IPO of ₹655.37 shares. The face value of each Corona Remedies share is ₹10. 

What is the issue price of Riddhi Display Equipment’s IPO?

The Corona Remedies IPO issue price band is set at ₹1008.00 to ₹1062.00 per share. Retail investors can apply for a minimum of 1 lot, each consisting of 14 shares, worth ₹14,868. Moreover, HNIs are required to bid for a minimum of 14 lots (196 shares) worth ₹2,08,152.

Who is the registrar of Riddhi Display Equipment’s IPO?

Bigshare Services Private Limited is the registrar for the Corona Remedies IPO, awaiting to manage the allotment process and initiate refunds. For any queries regarding the Corona Remedies allotment and refund, you can contact Bigshare Services Private Limited at ipo@bigshareonline.com or +91-22-6263 8200.

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Corona Remedies IPO, download the Corona Remedies IPO RHP and Corona Remedies IPO DRHP. Conduct your research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Recent Articles

Ravelcare IPO GMP: Day 3 IPO Live Updates

Astron Multigrain IPO Subscription Day 2

Astron Multigrain IPO GMP: Day 2 IPO Live Updates

Invicta Diagnostic IPO Subscription Day 2

Invicta Diagnostic IPO GMP: Day 2 IPO Live Updates

Corona Remedies IPO GMP & Review: Apply or Avoid?